High-risk myeloma: a gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
Open Access
- 15 January 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (2) , 968-969
- https://doi.org/10.1182/blood-2007-10-119321
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signatureLeukemia, 2007
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibBlood, 2006
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Gene expression profiling of pediatric acute myelogenous leukemiaBlood, 2004
- Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemiaCancer Cell, 2002
- Signatures of the Immune ResponseImmunity, 2001